Mice suffering from age-related heart disease saw a significant improvement in cardiac function after treatment with the FDA-approved drug rapamycin for just three months. Research at the Buck Institute shows how rapamycin impacts mammalian tissues, providing functional insights and possible benefits for a drug that can extend lifespan in mice as much as 14 percent. Researchers at the Mayo clinic are now recruiting seniors with cardiac artery disease for a clinical trial involving the drug.
↧
